GEN Exclusives

More »

GEN News Highlights

Back to Item »

Phase III Study Shows Exelixis’ Cabozantinib Nearly Triples PFS in Metastatic Medullary Thyroid Cancer

Firm has recently completed NDA submission to FDA for MTC and continues development against other cancers.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?